Saya Bio, Maxigen Biotech Announce Strategic Osteoarthritis Collaboration

 Saya Biologics (Saya Bio), a Mexican biopharmaceutical company committed to expanding patient access to innovative, high-quality, and affordable biological treatments, and Maxigen Biotech Inc., an international company specializing in the development and manufacture of hyaluronic acid-based therapeutic solutions, announced a strategic agreement to launch a portfolio of osteoarthritis products to the Mexican market.

Under the terms of the agreement, Saya Bio will be responsible for regulatory registration, commercialization, and distribution of the products within Mexico. Meanwhile, Maxigen Biotech Inc. will manufacture and supply the finished products, leveraging its advanced technology platforms and internationally recognized quality standards.

“This collaboration represents a pivotal moment in our journey to revolutionize joint health management in Mexico,” said Adrian Garcia, CEO of Saya Bio. “With 1.5 million people affected by osteoarthritis in Mexico , there’s an urgent need for effective, accessible treatment options. By partnering with Maxigen Biotech Inc., we’re not just bringing products to market – we’re offering hope and mobility to patients who have been limited by joint pain. Their advanced hyaluronic acid formulations align perfectly with our mission to deliver innovative, cost-effective solutions that can significantly improve quality of life.”

For her part, Flora Liu, Head of Global Business Center of Maxigen Biotech Inc., expressed great enthusiasm about partnering with Saya Bio to expand the reach of hyaluronic acid solutions in Latin America. “This alliance reflects our shared commitment to providing high-quality products that support mobility, joint health, and better patient outcomes” she said.